• Events
  • MHC/TCR
  • VLP & Nanodiscs
  • PepTalk 2024 in San Diego

    Jan 4, 2024

    KACTUS will be exhibiting at PepTalk San Diego at booth #217. Stop by our booth to learn about our latest recombinant protein products for drug discovery.

    KACTUS is at Peptalk

    What is PepTalk?

    PepTalk provides a comprehensive program and innovative solutions for optimizing biotherapeutics. Conference tracks cover a range of topics including antibody engineering, bispecific antibody development, characterization of biologics, viral vector engineering, and protein expression platforms.

    Programs:


    • Antibody Discovery & Engineering Stream
       Intelligent Antibody Discovery Part 1
       Intelligent Antibody Discovery Part 2
    • Bispecific Antibody Development Stream
       Developability of Bispecific Antibodies
       Safety & Efficacy of Bispecific Antibodies
    • Characterization of Biotherapeutics & Vaccines Stream
       Characterization of Biotherapeutics
       Characterizing Protein Aggregates & Impurities
    • Vector Design & Delivery Stream
       Viral Vector Engineering
       Non-Viral Vector Engineering
    • Biotherapeutic Expression & Production Stream
       Cell Line Optimization
       Recombinant Protein Expression

    What can be found in our poster sessions?

    #A20: GPCR VLPs & Nanodiscs for Drug Discovery

    G protein-coupled receptors (GPCRs), also known as seven-transmembrane receptors, represent the most important class of drug targets. However, extraction and purification of membrane proteins like GPCRs, ion channels, and transporters are generally challenging due to low expression levels and the hydrophobic nature of transmembrane segments. To tackle this challenge, we have engineered and produced GPCRs in VLP and/or nanodisc formats, which have been successfully applied to GPCR antibody drug discovery and various in vitro assays.

    #B20: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

    When dealing with solid tumors lacking specific biomarkers, the effectiveness of adoptive T cell therapy using TCR-T treatments is limited. We believe that the absence of dependable, multifaceted MHC reagents has been a hindrance in the research and development of treatments for solid tumors. To address this unmet need, we have engineered MHC molecules in several formats with diverse applications and high stability. These improved, highly active MHC molecules have the potential to facilitate solid tumor research and development.

    Event Details:

    Venue: Hilton San Diego Bayfront, California, United States

    Dates: January 16 - 19, 2024

    KACTUS Booth: #217

    KACTUS Poster: #A20 & #B20

    Learn more about our offerings, our commitment to quality, and how we can be your partner in innovation and development at KACTUS.


    More from > Events MHC/TCR VLP & Nanodiscs